{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:47:21Z","timestamp":1794329241621,"version":"4.9.0"},"reference-count":122,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The term \u201cadvanced sarcoidosis\u201d is used for forms of sarcoidosis with a significant risk of loss of organ function or death. Advanced sarcoidosis often involves the lung and is described as \u201cadvanced pulmonary sarcoidosis\u201d (APS), which includes advanced pulmonary fibrosis, associated complications such as bronchiectasis and infections, and pulmonary hypertension. Although APS affects a small proportion of patients with sarcoidosis, it is the leading cause of poor outcomes, including death. Here we review the major patterns of APS with a focus on the current management as well as potential approaches for improved outcomes for this most serious sarcoidosis phenotype.<\/jats:p>","DOI":"10.1164\/rccm.202106-1366ci","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T12:47:01Z","timestamp":1637671621000},"page":"495-506","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":47,"title":["Management of Advanced Pulmonary Sarcoidosis"],"prefix":"10.1093","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8764-6538","authenticated-orcid":false,"given":"Rohit","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4663-7985","authenticated-orcid":false,"given":"Marc A.","family":"Judson","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4871-3862","authenticated-orcid":false,"given":"Robert P.","family":"Baughman","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"2026022021042950400_bib1","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis: an official American Thoracic Society Clinical Practice Guideline","volume":"201","author":"Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022021042950400_bib2","first-page":"280","article-title":"The indications for the treatment of sarcoidosis: Wells Law","volume":"34","author":"Baughman","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MCP.0000000000000612","article-title":"Advanced sarcoidosis","volume":"25","author":"Baughman","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"2026022021042950400_bib4","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1378\/chest.14-1120","article-title":"Racial difference in sarcoidosis mortality in the United States","volume":"147","author":"Mirsaeidi","year":"2015","journal-title":"Chest"},{"key":"2026022021042950400_bib5","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1183\/13993003.00457-2016","article-title":"Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis","volume":"48","author":"Jamilloux","year":"2016","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of mortality in pulmonary sarcoidosis","volume":"153","author":"Kirkil","year":"2018","journal-title":"Chest"},{"key":"2026022021042950400_bib7","first-page":"128","article-title":"Mortality among African American women with sarcoidosis: data from the Black Women\u2019s Health Study","volume":"30","author":"Tukey","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.rmed.2018.11.010","article-title":"Sarcoidosis deaths in the United States: 1999-2016","volume":"149","author":"Kearney","year":"2019","journal-title":"Respir Med"},{"key":"2026022021042950400_bib9","first-page":"119","article-title":"The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States","volume":"29","author":"Judson","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib10","first-page":"275","article-title":"Features of sarcoidosis associated with chronic disease","volume":"31","author":"Baughman","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1513\/AnnalsATS.201511-760OC","article-title":"Sarcoidosis in America: analysis based on health care use","volume":"13","author":"Baughman","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026022021042950400_bib12","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1183\/09031936.00187410","article-title":"Stage IV sarcoidosis: comparison of survival with the general population and causes of death","volume":"38","author":"Nardi","year":"2011","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-2600(13)70276-5","article-title":"An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study","volume":"2","author":"Walsh","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026022021042950400_bib14","doi-asserted-by":"crossref","first-page":"105997","DOI":"10.1016\/j.rmed.2020.105997","article-title":"Predictors of mortality in fibrosing pulmonary sarcoidosis","volume":"169","author":"Jeny","year":"2020","journal-title":"Respir Med"},{"key":"2026022021042950400_bib15","doi-asserted-by":"crossref","first-page":"1901747","DOI":"10.1183\/13993003.01747-2019","article-title":"Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry","volume":"55","author":"Shlobin","year":"2020","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","article-title":"BTS Clinical Statement on pulmonary sarcoidosis","volume":"76","author":"Thillai","year":"2021","journal-title":"Thorax"},{"key":"2026022021042950400_bib17","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib18","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/bmj.2.5261.1165","article-title":"Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after five years\u2019 observation","volume":"2","author":"Scadding","year":"1961","journal-title":"BMJ"},{"key":"2026022021042950400_bib19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1378\/chest.15-0615","article-title":"Histopathology of explanted lungs from patients with a diagnosis of pulmonary sarcoidosis","volume":"149","author":"Zhang","year":"2016","journal-title":"Chest"},{"key":"2026022021042950400_bib20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.rmed.2012.11.011","article-title":"Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis","volume":"107","author":"Mostard","year":"2013","journal-title":"Respir Med"},{"key":"2026022021042950400_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/17476348.2017.1281745","article-title":"Strategies for identifying pulmonary sarcoidosis patients at risk for severe or chronic disease","volume":"11","author":"Judson","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"2026022021042950400_bib22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1183\/09031936.00150609","article-title":"Chronic interstitial pneumonitis in end-stage sarcoidosis","volume":"35","author":"Shigemitsu","year":"2010","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib23","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.rmed.2018.08.008","article-title":"Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?","volume":"144S","author":"Collins","year":"2018","journal-title":"Respir Med"},{"key":"2026022021042950400_bib24","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/j.rmed.2013.10.014","article-title":"Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients","volume":"107","author":"Baughman","year":"2013","journal-title":"Respir Med"},{"key":"2026022021042950400_bib25","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.3390\/jcm9010142","article-title":"Computed tomography images of fibrotic pulmonary sarcoidosis leading to chronic respiratory failure","volume":"9","author":"Sawahata","year":"2020","journal-title":"J Clin Med"},{"key":"2026022021042950400_bib26","first-page":"154","article-title":"Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients","volume":"19","author":"Lewis","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib27","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1378\/chest.08-2569","article-title":"Airway involvement in sarcoidosis","volume":"136","author":"Polychronopoulos","year":"2009","journal-title":"Chest"},{"key":"2026022021042950400_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.autrev.2014.10.006","article-title":"The spectrum of opportunistic diseases complicating sarcoidosis","volume":"14","author":"Jamilloux","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2026022021042950400_bib29","doi-asserted-by":"crossref","first-page":"e8846","DOI":"10.1097\/MD.0000000000008846","article-title":"Severe infections in sarcoidosis: incidence, predictors and long-term outcome in a cohort of 585 patients","volume":"96","author":"Dur\u00e9ault","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2026022021042950400_bib30","doi-asserted-by":"crossref","first-page":"2000767","DOI":"10.1183\/13993003.00767-2020","article-title":"Risk of first and recurrent serious infection in sarcoidosis: a Swedish register-based cohort study","volume":"56","author":"Rossides","year":"2020","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1183\/09031936.00226911","article-title":"Global burden of chronic pulmonary aspergillosis complicating sarcoidosis","volume":"41","author":"Denning","year":"2013","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib32","doi-asserted-by":"crossref","first-page":"1602396","DOI":"10.1183\/13993003.02396-2016","article-title":"Chronic pulmonary aspergillosis complicating sarcoidosis","volume":"49","author":"Uzunhan","year":"2017","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib33","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1378\/chest.12-1784","article-title":"A modern series of percutaneous intracavitary instillation of amphotericin B for the treatment of severe hemoptysis from pulmonary aspergilloma","volume":"143","author":"Kravitz","year":"2013","journal-title":"Chest"},{"key":"2026022021042950400_bib34","doi-asserted-by":"crossref","first-page":"1700465","DOI":"10.1183\/13993003.00465-2017","article-title":"Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib35","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1378\/chest.129.5.1246","article-title":"Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis","volume":"129","author":"Handa","year":"2006","journal-title":"Chest"},{"key":"2026022021042950400_bib36","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1183\/09031936.05.00083404","article-title":"Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics","volume":"25","author":"Shorr","year":"2005","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib37","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1055\/s-0040-1713615","article-title":"Sarcoidosis-associated pulmonary hypertension","volume":"41","author":"Huitema","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"2026022021042950400_bib38","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1378\/chest.09-2002","article-title":"Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation","volume":"138","author":"Baughman","year":"2010","journal-title":"Chest"},{"key":"2026022021042950400_bib39","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022021042950400_bib40","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1183\/09031936.00025212","article-title":"Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function","volume":"40","author":"Nunes","year":"2012","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib41","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1378\/chest.130.6.1851","article-title":"Clinical and radiographic indices associated with airflow limitation in patients with sarcoidosis","volume":"130","author":"Handa","year":"2006","journal-title":"Chest"},{"key":"2026022021042950400_bib42","doi-asserted-by":"crossref","first-page":"1900371","DOI":"10.1183\/13993003.00371-2019","article-title":"Radiomic measures from chest high-resolution computed tomography associated with lung function in sarcoidosis","volume":"54","author":"Ryan","year":"2019","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1378\/chest.12-2479","article-title":"Accuracy of individual variables in the monitoring of long-term change in pulmonary sarcoidosis as judged by serial high-resolution CT scan data","volume":"145","author":"Zappala","year":"2014","journal-title":"Chest"},{"key":"2026022021042950400_bib44","first-page":"90","article-title":"Endpoints for clinical trials of sarcoidosis","volume":"29","author":"Baughman","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib45","doi-asserted-by":"crossref","first-page":"190146","DOI":"10.1183\/16000617.0146-2019","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur Respir Rev"},{"key":"2026022021042950400_bib46","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/myc.12075","article-title":"Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature","volume":"56","author":"Agarwal","year":"2013","journal-title":"Mycoses"},{"key":"2026022021042950400_bib47","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1378\/chest.11-0324","article-title":"Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007","volume":"140","author":"Swigris","year":"2011","journal-title":"Chest"},{"key":"2026022021042950400_bib48","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.rmed.2013.01.004","article-title":"Concomitant sarcoidosis and a connective tissue disease: review of the clinical findings and postulations concerning their association","volume":"107","author":"Judson","year":"2013","journal-title":"Respir Med"},{"key":"2026022021042950400_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/02770903.2012.747204","article-title":"Distinguishing asthma from sarcoidosis: an approach to a problem that is not always solvable","volume":"50","author":"Kalkanis","year":"2013","journal-title":"J Asthma"},{"key":"2026022021042950400_bib50","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/ajrccm.163.2.2004177","article-title":"Depression in sarcoidosis","volume":"163","author":"Chang","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022021042950400_bib51","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1183\/09031936.00002512","article-title":"Sarcoidosis-associated fatigue","volume":"40","author":"Drent","year":"2012","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib52","first-page":"282","article-title":"Anxiety, its relation to symptoms severity and anxiety sensitivity in sarcoidosis","volume":"30","author":"Holas","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib53","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib54","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.rmed.2018.02.009","article-title":"Efficacy and safety of infliximab biosimilar Inflectra\u00ae in severe sarcoidosis","volume":"138S","author":"Schimmelpennink","year":"2018","journal-title":"Respir Med"},{"key":"2026022021042950400_bib55","first-page":"372","article-title":"Role of serial F-18 FDG PET\/CT scans in assessing treatment response and predicting relapses in patients with symptomatic sarcoidosis","volume":"33","author":"Maturu","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00408-017-9994-4","article-title":"Repository corticotropin for chronic pulmonary sarcoidosis","volume":"195","author":"Baughman","year":"2017","journal-title":"Lung"},{"key":"2026022021042950400_bib57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"Khan","year":"2017","journal-title":"Respir Med"},{"key":"2026022021042950400_bib58","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.rmed.2015.01.019","article-title":"The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis","volume":"109","author":"Judson","year":"2015","journal-title":"Respir Med"},{"key":"2026022021042950400_bib59","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/MCP.0000000000000078","article-title":"Cytotoxic agents in sarcoidosis: which one should we choose?","volume":"20","author":"Vorselaars","year":"2014","journal-title":"Curr Opin Pulm Med"},{"key":"2026022021042950400_bib60","first-page":"43","article-title":"Leflunomide for chronic sarcoidosis","volume":"21","author":"Baughman","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib61","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.rmed.2014.09.013","article-title":"Efficacy of mycophenolate mofetil in sarcoidosis","volume":"108","author":"Hamzeh","year":"2014","journal-title":"Respir Med"},{"key":"2026022021042950400_bib62","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial","volume":"17","author":"Baughman","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib63","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"Vorselaars","year":"2013","journal-title":"Chest"},{"key":"2026022021042950400_bib64","first-page":"e2020001","article-title":"Methotrexate in sarcoidosis: hematologic and hepatic toxicity encountered in a large cohort over a six year period","volume":"37","author":"Baughman","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib65","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.ophtha.2008.04.026","article-title":"Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation","volume":"115","author":"Galor","year":"2008","journal-title":"Ophthalmology"},{"key":"2026022021042950400_bib66","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamaoncol.2016.6435","article-title":"Association of therapy for autoimmune disease with myelodysplastic syndromes and acute myeloid leukemia","volume":"3","author":"Ertz-Archambault","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026022021042950400_bib67","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1183\/09031936.00195010","article-title":"Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis","volume":"38","author":"Sahoo","year":"2011","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib68","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1212\/WNL.0000000000003431","article-title":"Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil","volume":"87","author":"Bitoun","year":"2016","journal-title":"Neurology"},{"key":"2026022021042950400_bib69","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022021042950400_bib70","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/17512433.2018.1486706","article-title":"Treatment of sarcoidosis: grading the evidence","volume":"11","author":"James","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026022021042950400_bib71","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.semarthrit.2018.10.005","article-title":"Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety","volume":"48","author":"Adler","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2026022021042950400_bib72","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2016.04.011","article-title":"Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab","volume":"115","author":"Crommelin","year":"2016","journal-title":"Respir Med"},{"key":"2026022021042950400_bib73","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"key":"2026022021042950400_bib74","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"Judson","year":"2014","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib75","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2026022021042950400_bib76","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1183\/09031936.00055213","article-title":"Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis","volume":"43","author":"Vorselaars","year":"2014","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib77","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1183\/09031936.00224513","article-title":"Rituximab in the treatment of refractory pulmonary sarcoidosis","volume":"43","author":"Sweiss","year":"2014","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib78","doi-asserted-by":"crossref","first-page":"1753466619888127","DOI":"10.1177\/1753466619888127","article-title":"Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records","volume":"13","author":"Chopra","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"2026022021042950400_bib79","doi-asserted-by":"crossref","first-page":"1801482","DOI":"10.1183\/13993003.01482-2018","article-title":"Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia","volume":"52","author":"Rotenberg","year":"2018","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib80","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N Engl J Med"},{"key":"2026022021042950400_bib81","first-page":"100004","article-title":"Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents","volume":"1","author":"Sharp","year":"2019","journal-title":"Respir Med X"},{"key":"2026022021042950400_bib82","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"2026022021042950400_bib83","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026022021042950400_bib84","first-page":"123","article-title":"18F-FDG PET as a predictor of pulmonary function in sarcoidosis","volume":"28","author":"Keijsers","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib85","first-page":"110","article-title":"Inhaled iloprost for sarcoidosis associated pulmonary hypertension","volume":"26","author":"Baughman","year":"2009","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib86","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1378\/chest.13-1766","article-title":"Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial","volume":"145","author":"Baughman","year":"2014","journal-title":"Chest"},{"key":"2026022021042950400_bib87","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1378\/chest.08-1881","article-title":"Treatment of sarcoidosis-associated pulmonary hypertension. a two-center experience","volume":"135","author":"Barnett","year":"2009","journal-title":"Chest"},{"key":"2026022021042950400_bib88","first-page":"82","article-title":"Treatment of sarcoidosis-associated pulmonary hypertension: a single centre retrospective experience using targeted therapies","volume":"31","author":"Keir","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib89","first-page":"S0012-3692(21)03613-8","article-title":"Riociguat for sarcoidosis-associated pulmonary hypertension: results of a 1-year double-blind, placebo-controlled trial","author":"Baughman","year":"2021","journal-title":"Chest"},{"key":"2026022021042950400_bib90","first-page":"281","article-title":"Pulmonary stenting for the treatment of sarcoid induced pulmonary vascular stenosis","volume":"33","author":"Condado","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib91","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/crj.12435","article-title":"Interventional therapy in sarcoidosis-associated pulmonary arterial stenosis and pulmonary hypertension","volume":"11","author":"Liu","year":"2017","journal-title":"Clin Respir J"},{"key":"2026022021042950400_bib92","first-page":"e2021035","article-title":"Roflumilast (Daliresp) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial. Vol 38","volume":"38","author":"Baughman","year":"2021","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib93","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijsu.2011.01.002","article-title":"Clinical profile and surgical outcome for pulmonary aspergilloma: nine year retrospective observational study in a tertiary care hospital","volume":"9","author":"Khan","year":"2011","journal-title":"Int J Surg"},{"key":"2026022021042950400_bib94","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1510\/icvts.2011.265553","article-title":"Surgery for aspergilloma: time trend towards improved results?","volume":"13","author":"Lejay","year":"2011","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2026022021042950400_bib95","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1148\/radiology.146.3.6828674","article-title":"Management of massive hemoptysis by bronchial artery embolization","volume":"146","author":"Uflacker","year":"1983","journal-title":"Radiology"},{"key":"2026022021042950400_bib96","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1439-0507.1988.tb03653.x","article-title":"The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987)","volume":"31","author":"De Beule","year":"1988","journal-title":"Mycoses"},{"key":"2026022021042950400_bib97","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0190-9622(90)70263-H","article-title":"Itraconazole therapy in aspergillosis: study in 49 patients","volume":"23","author":"Dupont","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"2026022021042950400_bib98","first-page":"87","article-title":"Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy","volume":"37","author":"Syed","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib99","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1002\/hsr2.109","article-title":"Daily life physical activity in patients with chronic stage IV sarcoidosis: a multicenter cohort study","volume":"2","author":"Froidure","year":"2019","journal-title":"Health Sci Rep"},{"key":"2026022021042950400_bib100","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/HCR.0000000000000307","article-title":"Efficacy of a structured exercise program for improving functional capacity and quality of life in patients with stage 3 and 4 sarcoidosis: a randomized controlled trial","volume":"38","author":"Naz","year":"2018","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"2026022021042950400_bib101","first-page":"43","article-title":"Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: a pilot study","volume":"32","author":"Strookappe","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib102","author":"International Thoracic Organ Transplant (TTX) Registry Data Slides","year":"2019"},{"key":"2026022021042950400_bib103","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1378\/chest.122.1.233","article-title":"Outcomes for patients with sarcoidosis awaiting lung transplantation","volume":"122","author":"Shorr","year":"2002","journal-title":"Chest"},{"key":"2026022021042950400_bib104","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.rmed.2019.09.001","article-title":"Mortality for sarcoidosis patients on the transplant wait list in the Lung Allocation Score era: experience from a high volume center","volume":"157","author":"Gangemi","year":"2019","journal-title":"Respir Med"},{"key":"2026022021042950400_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","article-title":"A consensus document for the selection of lung transplant candidates: 2014\u2013an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation","volume":"34","author":"Weill","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"2026022021042950400_bib106","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1378\/chest.125.3.990","article-title":"Sarcoidosis, race, and short-term outcomes following lung transplantation","volume":"125","author":"Shorr","year":"2004","journal-title":"Chest"},{"key":"2026022021042950400_bib107","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1055\/s-0040-1709495","article-title":"Advanced pulmonary sarcoidosis","volume":"41","author":"Gupta","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"2026022021042950400_bib108","first-page":"117","article-title":"Bronchiolitis obliterans syndrome and survival following lung transplantation for patients with sarcoidosis","volume":"25","author":"Wille","year":"2008","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib109","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/thoraxjnl-2015-207497","article-title":"Lung transplantation for pulmonary sarcoidosis: twenty-five years of experience in the USA","volume":"71","author":"Taimeh","year":"2016","journal-title":"Thorax"},{"key":"2026022021042950400_bib110","doi-asserted-by":"crossref","first-page":"2003358","DOI":"10.1183\/13993003.03358-2020","article-title":"Lung transplantation for sarcoidosis: outcome and prognostic factors","volume":"58","author":"Le Pavec","year":"2021","journal-title":"Eur Respir J"},{"key":"2026022021042950400_bib111","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11916-011-0180-8","article-title":"Sarcoidosis and small-fiber neuropathy","volume":"15","author":"Tavee","year":"2011","journal-title":"Curr Pain Headache Rep"},{"key":"2026022021042950400_bib112","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/00007611-199709000-00010","article-title":"Is there an anatomic explanation for chest pain in patients with pulmonary sarcoidosis?","volume":"90","author":"Highland","year":"1997","journal-title":"South Med J"},{"key":"2026022021042950400_bib113","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000314225","article-title":"Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment","volume":"80","author":"Elfferich","year":"2010","journal-title":"Respiration"},{"key":"2026022021042950400_bib114","doi-asserted-by":"crossref","first-page":"00141-2018","DOI":"10.1183\/23120541.00141-2018","article-title":"Sarcoidosis: patient treatment priorities","volume":"4","author":"Baughman","year":"2018","journal-title":"ERJ Open Res"},{"key":"2026022021042950400_bib115","first-page":"1179","article-title":"Reduction of exercise capacity in sarcoidosis in relation to disease severity","volume":"9","author":"Kallianos","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"2026022021042950400_bib116","first-page":"147","article-title":"Pulmonary and psychosocial findings at enrollment in the ACCESS study","volume":"22","author":"Yeager","year":"2005","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib117","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MCP.0000000000000602","article-title":"Patient perspectives in sarcoidosis","volume":"25","author":"van Helmondt","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"2026022021042950400_bib118","first-page":"1","article-title":"Long-term effects of pulmonary rehabilitation on daily life physical activity of patients with stage IV sarcoidosis: a randomized controlled trial","volume":"77","author":"Wallaert","year":"2020","journal-title":"Respir Med Res"},{"key":"2026022021042950400_bib119","first-page":"e2020009","article-title":"Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire","volume":"37","author":"Baughman","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib120","first-page":"e2021029","article-title":"COVID-19 infections in sarcoidosis: a prospective single center study of 886 sarcoidosis patients","volume":"38","author":"Baughman","year":"2021","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026022021042950400_bib121","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00408-020-00392-9","article-title":"Moderate or severe impairment in pulmonary function is associated with mortality in sarcoidosis patients infected with SARS-CoV-2","volume":"198","author":"Morgenthau","year":"2020","journal-title":"Lung"},{"key":"2026022021042950400_bib122","doi-asserted-by":"crossref","first-page":"672028","DOI":"10.3389\/fmed.2021.672028","article-title":"COVID-19 and sarcoidosis, readiness for vaccination: challenges and opportunities","volume":"8","author":"Manansala","year":"2021","journal-title":"Front Med (Lausanne)"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/205\/5\/495\/67008934\/ajrccm_205_5_495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/205\/5\/495\/67008934\/ajrccm_205_5_495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:04:50Z","timestamp":1771639490000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/205\/5\/495\/8492115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":122,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3,1]]},"published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202106-1366ci","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3]]},"published":{"date-parts":[[2022,3,1]]},"assertion":[{"value":"2021-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}